This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Bortezomib in Treating Patients With Chronic Myelogenous Leukemia

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
M.D. Anderson Cancer Center Identifier:
First received: September 13, 2001
Last updated: October 5, 2012
Last verified: October 2012

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of bortezomib in treating patients who have chronic myelogenous leukemia in chronic or accelerated phase.

Condition Intervention Phase
Leukemia Drug: bortezomib Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Study of a Proteasome Inhibitor, PS-341 (NSC 681239) in Chronic Myelogenous Leukemia (CML) in Chronic or Accelerated Phase

Resource links provided by NLM:

Further study details as provided by M.D. Anderson Cancer Center:

Enrollment: 7
Study Start Date: July 2001
Study Completion Date: March 2005
Primary Completion Date: March 2005 (Final data collection date for primary outcome measure)
Detailed Description:


  • Determine the efficacy of bortezomib, in terms of response rate, duration of response, and survival of patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic or accelerated phase.
  • Assess the toxicity of this drug in these patients.

OUTLINE: Patients receive bortezomib intravenous (IV) over 3-5 seconds twice weekly on weeks 1-2. Treatment repeats every 3 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: A total of 5-30 patients will be accrued for this study within 15-30 months.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Diagnosis of Philadelphia (Ph) chromosome-positive chronic myelogenous leukemia (CML) in chronic or accelerated phase, defined as having any of the following:

    • Peripheral blood (PB) or bone marrow (BM) blasts at least 10% but less than 30%
    • PB or BM blasts and promyelocytes at least 20%
    • PB or BM basophils at least 20%
    • Progressive splenomegaly (at least 10 cm confirmed twice at least 4 weeks apart or 50% increase in splenomegaly over 4 weeks)
    • Clonal evolution defined as the presence of additional cytogenetic abnormalities other than the Ph chromosome
    • Thrombocytopenia (platelet count less than 100,000/mm^3) unrelated to therapy
    • Hemoglobin less than 7 g/dL unrelated to therapy or bleeding
  • Failed prior treatment with imatinib mesylate or intolerant, unable, or unwilling to receive it
  • Ineligible for higher-priority or higher-efficacy regimens or protocols
  • No blastic phase CML



  • 18 and over

Performance status:

  • Eastern Cooperative Oncology Group (ECOG) 0-2

Life expectancy:

  • At least 18 weeks


  • See Disease Characteristics


  • Bilirubin no greater than 1.5 mg/dL


  • Creatinine no greater than 1.5 mg/dL OR
  • Creatinine clearance greater than 60 mL/min


  • No other concurrent illness that would preclude study entry
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception


Biologic therapy:

  • Not specified


  • No more than 2 prior cytotoxic regimens in addition to imatinib mesylate and/or hydroxyurea
  • At least 4 weeks since prior chemotherapy and recovered
  • Concurrent hydroxyurea and/or anagrelide allowed during first 2 courses

Endocrine therapy:

  • Not specified


  • At least 4 weeks since prior radiotherapy and recovered


  • Not specified


  • See Disease Characteristics
  • See Chemotherapy
  • At least 24 hours since prior imatinib mesylate
  • No other concurrent investigational agents
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00023881

United States, Texas
MD Anderson Cancer Center at University of Texas
Houston, Texas, United States, 77030-4009
Sponsors and Collaborators
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Study Chair: Jorge Cortes, MD M.D. Anderson Cancer Center
  More Information

Responsible Party: M.D. Anderson Cancer Center Identifier: NCT00023881     History of Changes
Other Study ID Numbers: CDR0000068872
DM00-274 ( Other Identifier: UT MD Anderson Cancer Center )
Study First Received: September 13, 2001
Last Updated: October 5, 2012

Keywords provided by M.D. Anderson Cancer Center:
relapsing chronic myelogenous leukemia
chronic phase chronic myelogenous leukemia
accelerated phase chronic myelogenous leukemia
chronic myelogenous leukemia, BCR-ABL1 positive

Additional relevant MeSH terms:
Leukemia, Myeloid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Neoplasms by Histologic Type
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases
Proteasome Inhibitors
Antineoplastic Agents
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on August 16, 2017